0001415889-24-016672.txt : 20240613
0001415889-24-016672.hdr.sgml : 20240613
20240613161542
ACCESSION NUMBER: 0001415889-24-016672
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240611
FILED AS OF DATE: 20240613
DATE AS OF CHANGE: 20240613
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Posard Matthew L.
CENTRAL INDEX KEY: 0001543792
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32335
FILM NUMBER: 241041417
MAIL ADDRESS:
STREET 1: 11099 N. TORREY PINES ROAD
STREET 2: SUITE 100
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HALOZYME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001159036
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 880488686
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 794-8889
MAIL ADDRESS:
STREET 1: 12390 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: HALOZYME THERAPEUTICS INC
DATE OF NAME CHANGE: 20040312
FORMER COMPANY:
FORMER CONFORMED NAME: GLOBAL YACHT SERVICES INC
DATE OF NAME CHANGE: 20010912
4
1
form4-06132024_080638.xml
X0508
4
2024-06-11
0001159036
HALOZYME THERAPEUTICS, INC.
HALO
0001543792
Posard Matthew L.
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL
SAN DIEGO
CA
92130
true
false
false
false
0
Common Stock
2024-06-11
4
S
0
10000
50.011
D
109755
D
Common Stock
2024-06-12
4
S
0
10000
50.619
D
99755
D
Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
/s/ James Oehler, Attorney-in-Fact
2024-06-13